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HYDROCHLOROTHIAZIDE IN THE TREATMENT OF 
CONGESTIVE HEART FAILURE 
JOHN W . KEYES, M.D., GERALD M . BRENEMAN, M.D., AND 
HERNAN ALVAREZ, JR., M.D. 
INTRODUCTION: 
The past two years has seen the introduction to the medical profession of a 
new class of potent oral diuretic agents, derived from the aromatic sulfonamides and 
belonging to a group known as benzothiadiazines. This major break-through in 
producing a non-toxic and highly active oral diuretic resulted in the development 
of chlorothiazide, 6-chloro, 7-sulfamyl, 1, 2, 4-benzothiadiazine-l, 1-dioxide.' Since 
then, a second and more powerful derivative, hydrochlorothiazide, has been synthesized 
and is designated as 6-chloro-7-sulfamyl-3, 4-dihydro-I, 2, 4-benzothiadiazine-l, 1-di-
oxide. Figure 1. 
So, 
Figure 1 
Both compounds are active saluretic agents, causing the excrefion of large 
amounts of sodium, chloride and to a lesser extent, potassium. It is to this activity 
that they owe their effectiveness in the management of edema states, particularly 
congestive heart failure. 
MODE OF ADMINISTRATION: 
The comparable dose to 500 mgms. of chlorothiazide has not been concluded 
upon by the writers, but would appear to be somewhere between 50 and 100 mgms. 
The plan was to match 50 mgms. of hydrochlorothiazide to 500 mgms. of chlorothiazide. 
Some cases appeared to do as well on this program, but others required 150 mgms. 
of hydrochlorothiazide each day to equal 1,000 mgms. of chlorothiazide. It would 
appear that if the effects of hydrochlorothiazide are more prolonged,^ a wider spacing 
of eight hours between doses might provide longer coverage and better diuretic 
effects. It also may be continued for long periods of extended therapy, the same as 
chlorothiazide, but caution must be used to avoid electrolyte depletion effects, as it 
does appear to depress chlorides more than chlorothiazide. 
This drug may be administered intravenously in its lyohydrochlorothiazide form, 
50 mgms. being diluted in 5 to 10 cc. of distilled water. This amount comes very 
close to equalling 2 cc. of mercaptomerin or meralluride in effectiveness. 
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METHOD OF STUDY: 
Thirty-two patients with congestive heart failure were treated with hydrochloro-
thiazide. Fourteen patients had arteriosclerotic heart disease and fourteen had rheu-
matic heart disease. Two patients had hypertensive heart disease, and there was one 
case each of congenital heart disease (probable atrial septal defect) and cor pulmonale. 
The subjects were divided into three grades of congestive failure, as follows: 
Table 1 
GRADE 1: Patients with mild to moderate degrees of congestive heart failure, 
manifested usually by dyspnea, moist basilar rales, hepatic congestion and slight edema. 
GRADE I I : Patients with severe congestive failiire, usually with marked edema 
and/or ascites. 
GRADE 111: Patients with severe congestive failure who had become resistant 
or refractive to previously used diuretic agents. 
All patients were digitalized and the majority had received prior diuretic therapy, 
mercurials and/or chlorothiazide. One patient in grade I failure, and one in grade I I , 
had received no previous diuretic. Grade I patients were maintained on 400 to 1,600 
mgms. sodium diets as indicated, while those in grades I I and I I I were maintained 
on the 400 mgms. sodium diet. 
TABLE I 
ETIOLOGY GRADE I 
GRADE 
I I 
GRADE 
I I I TOTAL 
ARTERIOSCLEROTIC 4 (1) 7 (2) 3 14 
RHEUMATIC 3 10 1 (1) 14 
HYPERTENSIVE 1 1 0 2 
CONGENITAL 0 1 0 1 
COR PULMONALE 0 1 0 1 
TOTAL 8 20 4 32 
( ) toxic changes 
Twenty-four patients were hospitalized and the remaining eight were followed 
at one to four week intervals in the Out-Patient Department. A daily weight was 
obtained. Blood counts, urinalyses, BUN and serum electrolyte determinations once 
or twice weekly were obtained on all hospitalized patients. Clinic patients were 
checked with less regularity, though several maintained a daily weight chart at home. 
RESULTS 
GRADE I : Eight cases were classified as having grade I congestive failure, 
four with arteriosclerotic heart disease, three with rheumatic heart disease and one 
with hypertensive heart disease. Seven of the patients had been treated with previous 
diuretic programs, all with good response. When changed to hydrochlorothiazide, six 
of the seven responded equally well to this agent. One case (Case 1) demonstrated 
a superior response to a mercurial diuretic. 
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CASE 1: N.A. was a 71 year old white woman who had been followed in 
the Out-Patient Department since March 1957 with a diagnosis of rheumatic heart 
disease, aortic insufficiency and cardiac decompensation. She was maintained on 
a 1 gram salt diet, gitaligin 0.5 mgms. daily, and intermittent injections of mercurial 
diuretics. 
She was admitted to the hospital on December 14, 1958, because of increasinc 
dyspnea, palpitation and ankle edema of two weeks duration. Weight on admission 
was 106 pounds, and after four days of bedrest and her prior regime, her weight 
decreased to 10414 pounds. Seventy mgms. of lyohydrodiuril was administered at 
this time with a loss of VA pounds. Four days later an injection of 2 cc. of mer-
cuhydrin resulted in a diuresis of 4 4 pounds. During this four day interval the 
patient showed no evidence of the delayed response to hydrochlorothiazide mentioned 
below. 
One patient in this group not previously treated with diuretics showed a good 
response. 
No toxicity was noted other than weakness in one case after three days of drug 
administration. This patient had an acute myocardial infraction and could not be 
weighed, but daily urinary output indicated a good diuresis and the serum chloride 
level fell to 84 mEq. This cleared promptly when the drug was discontinued. 
GRADE I I : There were 20 cases in this group, seven with arteriosclerotic heart 
disease, ten with rheumatic heart disease, and one case each of congenital heart disease, 
chronic cor pulmonale, and hypertensive heart disease. 
One patient had not had previous treatment with diuretics and showed a good 
response. Of the remaining 19 cases, all had received previous diuretics with a 
satisfactory response, though the congestive heart failure was not completely controlled 
in all cases. Seventeen of the 19 cases showed a good response with a weight loss of 
one to 27 pounds after hydrochlorothiazide was started, the average being seven 
pounds. Thus, 18 of the 20 cases had a satisfactory diuretic response. Four pafients 
previously maintained on chlorothiazide as the sole diuretic were felt to have an im-
proved diuresis with hydrochlorothiazide. 
CASE 2: A.D., a 73 year old woman with arteriosclerotic heart disease, chronic 
atrial fibrillation and chronic congestive heart failure was followed in the Out-Patient 
Department. Her passive congestion was incompletely controlled on a 1 gram salt diet, 
digitoxin 0.1 mgms. daily, diuril 500 mgms. twice daily three days each week and 
ammonium chloride. Hydrodiuril 50 mgms. b.i.d. was substituted for the diuril three 
days each week with a prompt loss of 6V2 pounds, and considerable improvement in 
her hepatomegaly and edema, though still not at a dry weight. 
In several cases, a prolonged diuresis with a delayed maximal response was noted, 
partricularly following intravenous administration. This, to our knowledge, has not 
previously been reported. 
190 
Hydrochlorothiazide in Heart Failure 
CASE 3: L.D. (Fig. I ) a 46 year old white man, was admitted to the hospital 
on December 31, 1958. For two years prior to admission he had increasing dyspnea 
on exertion, cyanosis, ascites and pedal edema.. There was a life-long history of 
bronchial asthma. Previous treatment included a low salt diet, digitalis and intermittent 
injections of mercurial diuretics. 
Cardiac catheterization showed no evidence of a shunt. Diagnoses of chronic 
cor pulmonale, obstructive emphysema and congestive heart failure were made. 
The patient was continued on digitoxin and a 1 gram salt diet. During the first 
week he diuresed 14 pounds with bedrest and two injections of mercaptomerin. On 
January 8, 1959, the patient weighed 202-% pounds, and was given 50 mgms. of 
lyohydrochlorothiazide intravenously. The following morning he weighed 200% 
pounds, and on the day following — 1921/2 pounds. The same intravenous dose was 
repeated, and over the next four day period, he diuresed an additional 13 pounds. 
200 - -
^50 mgms, Hyrdrodixiril I.V* 
175 -^t 
8 9 10 11 12 13 14 15 1 6 ^ 
FIGURE I 
Two patients in this group responded poorly to hydrochlorothiazide in a dose 
of 100 mgms. daily. A larger dose might have proven effective, though in our 
experience some effect can usually be obtained at this dosage level if the patient 
will respond at all to the drug. 
Nausea and weakness occurred in one patient of this group who asked that 
the drug be discontinued. Serum electrolytes in this case were normal. Weakness 
and anorexia were noted by a second patient, but drug withdrawal was not necessary. 
Mild to moderate degrees of hypochloremia were not uncommon, but caused no 
untoward effects. No cases of hyponatremia or hypokalemia were noted in this series, 
but these complications have been observed by the authors since preparation of 
this report. 
GRADE I I I : Four cases of severe, resistant congestive heart failure were given 
a trial of hydrochlorothiazide. Three were cases of advanced arteriosclerotic heart 
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disease and there was one case of rheumatic heart disease. Al l had developed re-
fractoriness to mercurial diuretics and diuril, and showed no response to hydrochloro-
thiazide. Two patients subsequently showed some response to mercurial diuretics 
when started on large doses of triamcinolone. 
No toxic effects directly attributable to hydrochlorothiazide were noted in these 
seriously ill patients. One case developed paroxysmal ventricular tachycardia twelve 
hours after receiving 50 mgms. of hydrodiuril intravenously. This converted readily 
during the administration of 40 mEq. of potassium in 500 cc. of 5% glucose in water. 
There were no other signs of possible digitalis toxicity while the serum electrolytes 
determined at the time showed only a mild hyponatremia (Na 127 mEq.). The 
relation to hydrochlorothiazide is conjectural. 
COMMENT: 
Hydrochlorothiazide, like chlorothiazide, causes a marked excretion of sodium, 
chloride and potassium in the urine, apparently due to a renal tubular blocking 
action on the reabsorption of these ions. Studies by Moyer and co-workers'" suggest 
that the primary action is on chloride excretion in contrast to chlorothiazide, which 
produces a relatively greater loss of sodium. The two drugs appear to cause ap-
proximately equal excretion of potassium. The saluretic effects are greater and more 
prolonged in the case of hydrochlorothiazide at a comparable oral dose.^  The latter 
effect was noted over a protracted period in one of the cases in this report (Case 3). 
Diuresis is apparently improved when acid salts, potassium chloride and/or ammonium 
chloride were used as adjunctive therapy in this series. It was somewhat less effective 
when serum chlorides were at slightly depressed levels and much less effective at 
moderately depressed levels, i.e. when serum chlorides were depressed after intensive 
or prolonged therapy below 97 mEq. 
Hydrochlorothiazide is well tolerated orally and almost devoid of gastrointestinal 
side effects, even in the most advanced cases of congestive heart failure whh severe 
visceral congestion. Like chlorothiazide, it remains consistently effective without 
evidence of drug tolerance and subsequent need of increasing dosage. Approximately 
two percent of our cases treated with chlorothiazide have developed a mild erythematous 
skin rash, while none were encountered in this series treated with hydrochlorothiazide. 
No adequate opportunity has been afforded to test the latter drug in a patient sensitive 
to chlorothiazide. Hydrochlorothiazide has not produced any toxic renal disturbance 
since it use was begun. Jaundice has not been reported to date, though this is a rare 
toxic complication with the use of chlorothiazide. 
The greatest danger and toxic effect appears to be severe electrolyte depletion. 
Mild hypochloremia is a natural consequence of the use of either of these two 
agents, but if large doses are given over too long a period in salt depleted patients, 
severe hypochloremic alkalosis, "salt depletion syndrome", and severe hypokalemic 
effects may be produced. The adjunctive use of potassium chloride orally, and/or 
ammonium chloride can prevent severe hypokalemia, or hypochloremia, and in our 
opinion, should be used where heavy dosage of both drugs are employed, particularly 
over long periods. If severe liver impairment is present, as is so often the case in 
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long-standing congestive heart failure, loss of potassium may already have occurred, 
and will be aggravated by this type of diuretic therapy. The depletion of potassium 
will lead to augmented digitalis effects with typical manifestations of digitalis intoxica-
tion, mild to severe, manifested often by unusual digitalis arrhythmias. The authors 
suspect one of the cases in this report was due to this effect. 
It is recommended that regular serum electrolyte determinations be obtained 
where prolonged administration is used in advanced chronic congestive heart failure, 
particularly where hepatic or renal disease may be suspected, or known to exist, and 
to "spot check" others at the slightest suspicion of electrolyte depletion. The latter 
should be suspected if sudden oliguria, or failure to respond, occurs. 
Hypochloremic alkalosis usually responds promptly to the use of ammonium 
chloride, and may be hastened by the combined use of a carbonic anhydrase inhibiting 
agent for several days. 
Hydrochlorothiazide represents another significant advance in the diuretic man-
agement of congestive heart failure, and like chlorothiazide, approaches the effective-
ness of parenterally administered mercurials. 
SUMMARY: 
Hydrochlorothiazide was administered to a series of thirty-two patients with 
congestive heart failure. It was a potent diuretic for the short or long term management 
of these cases, and can be administered by the oral or intravenous routes. Dosage 
and toxicity is discussed. 
Drug material for this study was supplied by Merck Sharpe and Dohme, Research Laboratories, 
Division of Merck and Co., Inc., Philadelphia, Pennsylvania. 
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